secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEAYA Biosciences, Inc. (IDYA)
CIK:        0001676725
Form:       8-K
Filed at:   2026-04-09T23:59:59+00:00
Accession:  0001193125-26-148777
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

IDEAYA enters clinical collaboration with AstraZeneca for IDE849 + Imfinzi in SCLC
--------------------------------------------------------------------------------

- Collaboration to evaluate IDE849 (DLL3 TOP1 ADC) plus AstraZeneca's Imfinzi in extensive-stage SCLC.
- IDEAYA sponsors the combination study; AstraZeneca supplies Imfinzi.
- IDE849 Phase 1 global trial ongoing in DLL3-upregulated solid tumors including SCLC, NECs, NETs, melanoma.
- No financial terms of the collaboration disclosed in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1676725/000119312526148777/0001193125-26-148777-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1676725/000119312526148777/d100891d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-148777

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer